The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig. Although these agents have improved the treatment outcomes considerably, most patients eventually stop responding and ultimately die of their disease. The currently available second-line CLL therapies are moderately satisfying in terms of efficacy, safety and tolerability, convenience of administration, and non-clinical factors, yet the remaining unmet need for more-efficacious and better-tolerated therapies presents a significant commercial opportunity

Table of contents

  • Detailed, Expanded Analysis (Second-line Chronic-Lymphocytic-Leukemia)
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in Second-line Chronic Lymphocytic Leukemia
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Second-line Chronic Lymphocytic Leukemia
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Unmet Need in Second-line Chronic Lymphocytic Leukemia and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Second-line Chronic Lymphocytic Leukemia Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy That Can Significantly Increase Overall Survival
        • Opportunity: A Therapy That Improves Complete Response Rate
        • Opportunity: A Novel Therapy with an Improved Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Author(s): Niamh Buckley

Niamh Buckley is a senior director in the oncology team at Decision Resources Group where she manages a team of analysts in producing syndicated and custom primary and secondary market research on a wide range of oncology indications. She also provides sales and client support for all oncology products. Dr. Buckley has extensive experience in market access and forecasting across oncology and hematology-oncology drug markets She also has considerable experience in conducting primary research with physicians and payers throughout the major pharmaceutical markets. Prior to joining Decision Resources, Dr. Buckley worked as a postdoctoral scientist focusing on translational breast cancer research. She has a in biotechnology and obtained her in molecular oncology from Trinity College in Ireland.


Related Reports

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over th...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2019

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Epidemiology | Mature Markets Non-Hodgkin's Lymphoma

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) comprises epidemiological estimat...

View Details